Literature DB >> 16426820

Mutant prevention concentration for ciprofloxacin and levofloxacin with Pseudomonas aeruginosa.

Glen T Hansen1, Xilin Zhao, Karl Drlica, Joseph M Blondeau.   

Abstract

The mutant prevention concentration (MPC) was determined by population analysis using six fluoroquinolone-susceptible isolates of Pseudomonas aeruginosa applied to fluoroquinolone-containing agar plates. The MPCs were 3 mg/L and 9.5 mg/L for ciprofloxacin and levofloxacin, respectively. At high concentrations of either compound, single-step gyrA resistance mutants were recovered. Using a modified method for estimating the MPC, 151 clinical isolates were surveyed. Modal MPCs were 2 mg/L and 8 mg/L, respectively, for ciprofloxacin and levofloxacin. Thus, ciprofloxacin is three to four times more active than levofloxacin against resistant mutant subpopulations. For individual isolates, the MPC correlated poorly with the minimum inhibitory concentration (r(2) = 0.41 and 0.39 for ciprofloxacin and levofloxacin, respectively).

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16426820     DOI: 10.1016/j.ijantimicag.2005.10.005

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  22 in total

Review 1.  A unified anti-mutant dosing strategy.

Authors:  Xilin Zhao; Karl Drlica
Journal:  J Antimicrob Chemother       Date:  2008-06-10       Impact factor: 5.790

2.  Comparative study of the mutant prevention concentrations of moxifloxacin, levofloxacin, and gemifloxacin against pneumococci.

Authors:  Kim Credito; Klaudia Kosowska-Shick; Pamela McGhee; Glenn A Pankuch; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2009-12-14       Impact factor: 5.191

3.  Effect of ciprofloxacin concentration on the frequency and nature of resistant mutants selected from Pseudomonas aeruginosa mutS and mutT hypermutators.

Authors:  Natalia R Morero; Mariela R Monti; Carlos E Argaraña
Journal:  Antimicrob Agents Chemother       Date:  2011-06-06       Impact factor: 5.191

Review 4.  What Antibiotic Exposures Are Required to Suppress the Emergence of Resistance for Gram-Negative Bacteria? A Systematic Review.

Authors:  Chandra Datta Sumi; Aaron J Heffernan; Jeffrey Lipman; Jason A Roberts; Fekade B Sime
Journal:  Clin Pharmacokinet       Date:  2019-11       Impact factor: 6.447

Review 5.  Pharmacokinetic characteristics of antimicrobials and optimal treatment of urosepsis.

Authors:  Florian M E Wagenlehner; Wolfgang Weidner; Kurt G Naber
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

Review 6.  Individualising Therapy to Minimize Bacterial Multidrug Resistance.

Authors:  A J Heffernan; F B Sime; J Lipman; J A Roberts
Journal:  Drugs       Date:  2018-04       Impact factor: 9.546

7.  Role of the MexEF-OprN efflux system in low-level resistance of Pseudomonas aeruginosa to ciprofloxacin.

Authors:  Catherine Llanes; Thilo Köhler; Isabelle Patry; Barbara Dehecq; Christian van Delden; Patrick Plésiat
Journal:  Antimicrob Agents Chemother       Date:  2011-09-12       Impact factor: 5.191

8.  Mutant prevention concentrations of four carbapenems against gram-negative rods.

Authors:  Kim Credito; Klaudia Kosowska-Shick; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2010-03-22       Impact factor: 5.191

9.  Local treatment of experimental Pseudomonas aeruginosa osteomyelitis with a biodegradable dilactide polymer releasing ciprofloxacin.

Authors:  Kyriaki Kanellakopoulou; George C Thivaios; Maria Kolia; Ismini Dontas; Lydia Nakopoulou; Eleftherios Dounis; Evangelos J Giamarellos-Bourboulis; Andreas Andreopoulos; Panayotis Karagiannakos; Helen Giamarellou
Journal:  Antimicrob Agents Chemother       Date:  2008-04-14       Impact factor: 5.191

10.  Meropenem Combined with Ciprofloxacin Combats Hypermutable Pseudomonas aeruginosa from Respiratory Infections of Cystic Fibrosis Patients.

Authors:  Vanessa E Rees; Rajbharan Yadav; Kate E Rogers; Jürgen B Bulitta; Veronika Wirth; Antonio Oliver; John D Boyce; Anton Y Peleg; Roger L Nation; Cornelia B Landersdorfer
Journal:  Antimicrob Agents Chemother       Date:  2018-10-24       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.